Lipid-lowering agents that cause drug-induced hepatotoxicity.
The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.
Bhardwaj
Sidharth S
SS
Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 1001 West 10th Street, WD OPW 2005, Indianapolis, IN 46202, USA.
Chalasani
Naga
N
D001384:Azetidines / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D009525:Niacin / Q000009:adverse effects
D001384:Azetidines; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D000069438:Ezetimibe